JPWO2023072177A5 - - Google Patents
Info
- Publication number
- JPWO2023072177A5 JPWO2023072177A5 JP2024524985A JP2024524985A JPWO2023072177A5 JP WO2023072177 A5 JPWO2023072177 A5 JP WO2023072177A5 JP 2024524985 A JP2024524985 A JP 2024524985A JP 2024524985 A JP2024524985 A JP 2024524985A JP WO2023072177 A5 JPWO2023072177 A5 JP WO2023072177A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/126597 | 2021-10-27 | ||
| PCT/CN2021/126597 WO2023070353A1 (en) | 2021-10-27 | 2021-10-27 | Anti-cd47 antibodies and methods of use thereof |
| PCT/CN2022/127875 WO2023072177A1 (en) | 2021-10-27 | 2022-10-27 | Anti-cd47 antibodies and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024542978A JP2024542978A (ja) | 2024-11-19 |
| JPWO2023072177A5 true JPWO2023072177A5 (https=) | 2025-10-29 |
| JP2024542978A5 JP2024542978A5 (https=) | 2025-10-29 |
Family
ID=86160307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024524985A Pending JP2024542978A (ja) | 2021-10-27 | 2022-10-27 | 抗ｃｄ４７抗体及びその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240417463A1 (https=) |
| EP (1) | EP4423138A4 (https=) |
| JP (1) | JP2024542978A (https=) |
| KR (1) | KR20240111823A (https=) |
| CN (1) | CN118434769A (https=) |
| AU (1) | AU2022376756A1 (https=) |
| CA (1) | CA3235611A1 (https=) |
| TW (1) | TW202334216A (https=) |
| WO (2) | WO2023070353A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025010272A1 (en) | 2023-07-03 | 2025-01-09 | Neoimmunetech, Inc. | Heterodimeric fc molecules and uses thereof |
| TW202517683A (zh) * | 2023-07-20 | 2025-05-01 | 美商艾克塞里克斯公司 | 可活化之ror結合劑及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2477648B1 (en) * | 2009-09-15 | 2022-07-20 | The Board of Trustees of the Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
| US9517276B2 (en) * | 2013-06-04 | 2016-12-13 | Cytomx Therapeutics, Inc. | Compositions and methods for conjugating activatable antibodies |
| EP3668897B1 (en) * | 2017-08-18 | 2024-06-05 | Centessa Pharmaceuticals (UK) Limited | Binding agents |
| KR20200091901A (ko) * | 2017-12-01 | 2020-07-31 | 시애틀 지네틱스, 인크. | 암을 치료하기 위한 cd47 항체 및 이의 용도 |
| EP3802599B1 (en) * | 2018-06-03 | 2023-12-20 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
| MA53333A (fr) * | 2018-07-31 | 2021-11-03 | Amgen Inc | Formulations pharmaceutiques d'anticorps masqués |
| US20220233709A1 (en) * | 2019-06-05 | 2022-07-28 | Seagen Inc. | Masked Antibody Formulations |
| US20220306727A1 (en) * | 2019-06-05 | 2022-09-29 | Seagen Inc. | Methods of Purifying Masked Antibodies |
| EP4034171A1 (en) * | 2019-09-23 | 2022-08-03 | Cytomx Therapeutics Inc. | Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof |
-
2021
- 2021-10-27 WO PCT/CN2021/126597 patent/WO2023070353A1/en not_active Ceased
-
2022
- 2022-10-27 JP JP2024524985A patent/JP2024542978A/ja active Pending
- 2022-10-27 EP EP22886052.4A patent/EP4423138A4/en active Pending
- 2022-10-27 TW TW111140895A patent/TW202334216A/zh unknown
- 2022-10-27 CA CA3235611A patent/CA3235611A1/en active Pending
- 2022-10-27 WO PCT/CN2022/127875 patent/WO2023072177A1/en not_active Ceased
- 2022-10-27 KR KR1020247017377A patent/KR20240111823A/ko active Pending
- 2022-10-27 AU AU2022376756A patent/AU2022376756A1/en active Pending
- 2022-10-27 CN CN202280084763.1A patent/CN118434769A/zh active Pending
- 2022-10-27 US US18/705,386 patent/US20240417463A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023254931B2 (en) | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof | |
| JP7596450B2 (ja) | 活性化可能抗体ならびにその作製及び使用方法 | |
| CA3071383C (en) | Anti-cd137 antibodies | |
| JP2021511808A5 (https=) | ||
| JP2021512122A5 (https=) | ||
| EP2609112B1 (en) | Activatable bispecific antibodies | |
| JPWO2019149281A5 (https=) | ||
| US9908944B2 (en) | Antibodies that bind urokinase plasminogen activator | |
| JP7832926B2 (ja) | 制約され、条件付きで活性化された結合タンパク質 | |
| RU2015101803A (ru) | Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения | |
| JPWO2020252264A5 (https=) | ||
| JPWO2019149282A5 (https=) | ||
| US12590159B2 (en) | Compositions targeting epidermal growth factor receptor and methods for making and using the same | |
| IL298815A (en) | Bispecific compositions targeting HER-2 and methods for their preparation and use | |
| JP2026505405A (ja) | 前立腺特異的膜抗原（ｐｓｍａ）を標的とする組成物、並びにそれを作製及び使用するための方法 | |
| JPWO2023072177A5 (https=) | ||
| JPWO2023193817A5 (https=) | ||
| JPWO2023169360A5 (https=) | ||
| US11512134B2 (en) | Anti-CD137 antibodies | |
| NZ767462B2 (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| NZ767462A (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| KR102825424B1 (ko) | SARS-CoV-2 및 면역세포 수용체에 결합하는 이중특이적 항체 및 이를 포함하는 약학 조성물 | |
| CN121949565A (zh) | 靶向表皮生长因子受体的组合物及其制备和使用方法 | |
| CN121712801A (zh) | 包含空间位阻部分的CyCAT半体分子 | |
| Gerspach | Activatable bispecific antibodies The current invention relates to bispecific antibodies wherein the binding affinity to one of the two antigens is reduced and which can be activated by tumor-or inflammation-tissue/disease specific proteases (eg tumor-or inflammation-specific proteases); and the preparation and use of such bispecific antibodies. |